Cipher Pharmaceuticals (CPHRF)
OTHER OTC:CPHRF
CPHRF Stock Chart & Stats
$10.87
-$0.10(-0.92%)
At close: 4:00 PM EST
$10.87
-$0.10(-0.92%)
Day’s Range― - ―
52-Week Range$8.64 - $15.00
Previous CloseN/A
Volume27.53K
Average Volume (3M)13.12K
Market Cap
$304.98M
Enterprise Value$301.19M
Total Cash (Recent Filing)$6.41M
Total Debt (Recent Filing)$428.30K
Price to Earnings (P/E)9.9
Beta0.15
Next Earnings
Aug 06, 2026EPS Estimate
0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.22
Shares Outstanding25,281,181
10 Day Avg. Volume17,096
30 Day Avg. Volume13,121
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)2.22
Price to Sales (P/S)5.44
P/FCF Ratio9.25
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue5.91
Enterprise Value/Gross Profit7.94
Enterprise Value/Ebitda11.99
Forecast
1Y Price Target
$15.89Price Target Upside46.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.63
Revenue Forecast (FY)$38.70M
Bulls Say, Bears Say
Bulls Say
High ProfitabilitySustained very high net margins (~54% TTM) indicate durable pricing power and/or low-cost structure in core products. High margins support internal reinvestment, M&A funding, and resilience to sales volatility, underpinning long-term cash earnings quality.
Strong Cash GenerationRobust free cash flow growth and high cash conversion (near 1:1 with reported profit) provide durable capacity for investment, licensing deals, and shareholder returns. Reliable FCF improves balance sheet optionality and supports long-term strategic initiatives.
Conservative Balance SheetVery low leverage gives the company flexibility to pursue acquisitions, absorb shocks, and invest in commercialization. A strong equity base and healthy ROE (low-20% range) support sustainable earnings quality and reduce refinancing risk over multiple quarters.
Bears Say
Earnings VolatilityPronounced year-to-year swings in profitability and reported debt suggest earnings may be influenced by non-recurring items, product mix shifts, or timing effects. This reduces predictability of future earnings and complicates planning for reinvestment and capital allocation.
Concentrated Commercial FootprintReliance on a narrow therapeutic focus and limited direct geographic reach concentrates commercial risk. A small internal team and focused product portfolio can amplify operational risks, making growth and execution dependent on a few products and markets.
Partner/licensing Revenue DependenceSignificant portion of revenue comes from licensing/partner arrangements outside direct markets. Long-term growth and margins therefore hinge on third-party partner execution, pricing/reimbursement in varied jurisdictions, and contract renewals, limiting company control.
Cipher Pharmaceuticals News
CPHRF FAQ
What was Cipher Pharmaceuticals’s price range in the past 12 months?
Cipher Pharmaceuticals lowest stock price was $8.63 and its highest was $15.00 in the past 12 months.
What is Cipher Pharmaceuticals’s market cap?
Cipher Pharmaceuticals’s market cap is $304.98M.
When is Cipher Pharmaceuticals’s upcoming earnings report date?
Cipher Pharmaceuticals’s upcoming earnings report date is Aug 06, 2026 which is in 64 days.
How were Cipher Pharmaceuticals’s earnings last quarter?
Cipher Pharmaceuticals released its earnings results on May 07, 2026. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.135 by $0.105.
Is Cipher Pharmaceuticals overvalued?
According to Wall Street analysts Cipher Pharmaceuticals’s price is currently Undervalued.
Does Cipher Pharmaceuticals pay dividends?
Cipher Pharmaceuticals does not currently pay dividends.
What is Cipher Pharmaceuticals’s EPS estimate?
Cipher Pharmaceuticals’s EPS estimate is 0.21.
How many shares outstanding does Cipher Pharmaceuticals have?
Cipher Pharmaceuticals has 25,281,181 shares outstanding.
What happened to Cipher Pharmaceuticals’s price movement after its last earnings report?
Cipher Pharmaceuticals reported an EPS of $0.24 in its last earnings report, beating expectations of $0.135. Following the earnings report the stock price went up 9.961%.
Which hedge fund is a major shareholder of Cipher Pharmaceuticals?
Currently, no hedge funds are holding shares in CPHRF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cipher Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.89 (46.17% Upside)
$15.89 (46.17% Upside)
Insider Transactions
Sold Shares
Worth $93.9K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-12.52%
12-Months-Change
Fundamentals
Return on Equity
25.69%
Trailing 12-Months
Asset Growth
-6.01%
Trailing 12-Months
Company Description
Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company's licensed products comprise CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and Conzip/Durela (CIP- Tramadol), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. Its pipeline products include Trevyent, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension; CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for the treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Oakville, Canada.
CPHRF Company Deck
CPHRF Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and significant debt reduction, supported by the robust performance of the Natroba business. However, challenges remain in licensing revenue and the Absorica portfolio, along with increased SG&A costs. Overall, the positive aspects slightly outweigh the negative aspects.View all CPHRF earnings summariesCPHRF Stock 12 Month Forecast
Average Price Target
$15.89
▲(46.17% Upside)
Technical Analysis
Knight Therapeutics
―
Medexus Pharmaceuticals Inc
―
Biosyent
―
HLS Therapeutics Inc
―
Cardiol Therapeutics
―
Ownership Overview
42.91% Insiders
0.94% Mutual Funds
2.60% Other Institutional Investors
53.48% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---